ArticlePLoS medicine2014
The importance of implementation strategy in scaling up Xpert MTB/RIF for diagnosis of tuberculosis in the Indian health-care system: a transmission model.
Article in PLoS medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03044158 (GeneXpert Performance Evaluation for Linkage to Tuberculosis Care), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
GeneXpert Performance Evaluation for Linkage to Tuberculosis Care: The XPEL-TB Trial
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Impact of molecular diagnostic tests on diagnostic and treatment delays in tuberculosis: a systematic review and meta-analysis.BMC infectious diseases · 2022Pooled it
- Evaluating the nationwide availability of essential diagnostics for tuberculosis toward achieving a TB-free India.Microbiology spectrum · 2026Article
- Evaluating the Gaps in the Diagnosis and Treatment in Extra-Pulmonary Tuberculosis Patients Under National Tuberculosis Elimination Programme (NTEP) Guidelines: A Multicentric Cohort Study.Tropical medicine and infectious disease · 2025Article
- Assessing potential insights of an imperfect testing strategy: Parameter estimation and practical identifiability using early COVID-19 data in India.Communications in nonlinear science & numerical simulation · 2023Article
- Costs and cost-effectiveness of a comprehensive tuberculosis case finding strategy in Zambia.PloS one · 2021Article
- Field sales force model to increase adoption of a novel tuberculosis diagnostic test among private providers: evidence from India.BMJ global health · 2020Article
- Predicting the impact of patient and private provider behavior on diagnostic delay for pulmonary tuberculosis patients in India: A simulation modeling study.PLoS medicine · 2020Article
- Closing gaps in the tuberculosis care cascade: an action-oriented research agenda.Journal of clinical tuberculosis and other mycobacterial diseases · 2020Review
- Informing decision-making for universal access to quality tuberculosis diagnosis in India: an economic-epidemiological model.BMC medicine · 2019Article
- Introducing risk inequality metrics in tuberculosis policy development.Nature communications · 2019Article
- Modelling the impact of effective private provider engagement on tuberculosis control in urban India.Scientific reports · 2019Article
- Constructing care cascades for active tuberculosis: A strategy for program monitoring and identifying gaps in quality of care.PLoS medicine · 2019Review
- New TB Tools Need to be Affordable in the Private Sector: The Case Study of Xpert MTB/RIF.Journal of epidemiology and global health · 2018Article
- Optimal timing of drug sensitivity testing for patients on first-line tuberculosis treatment.Health care management science · 2018Article
- Impact of involvement of non-formal health providers on TB case notification among migrant slum-dwelling populations in Odisha, India.PloS one · 2018Article
- Patient-Centered Tuberculosis Programs Are Necessary to End the Epidemic.The Journal of infectious diseases · 2017Article
- Designing and Evaluating Interventions to Halt the Transmission of Tuberculosis.The Journal of infectious diseases · 2017Review
- Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control.Microbiology spectrum · 2017Review
- Higher cost of implementing Xpert(®) MTB/RIF in Ugandan peripheral settings: implications for cost-effectiveness.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2016Observational
- Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?The European respiratory journal · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
Abstract
backgroundIndia has announced a goal of universal access to quality tuberculosis (TB) diagnosis and treatment. A number of novel diagnostics could help meet this important goal. The rollout of one such diagnostic, Xpert MTB/RIF (Xpert) is being considered, but if Xpert is used mainly for people with HIV or high risk of multidrug-resistant TB (MDR-TB) in the public sector, population-level impact may be limited. METHODS AND
findingsWe developed a model of TB transmission, care-seeking behavior, and diagnostic/treatment practices in India and explored the impact of six different rollout strategies. Providing Xpert to 40% of public-sector patients with HIV or prior TB treatment (similar to current national strategy) reduced TB incidence by 0.2% (95% uncertainty range [UR]: -1.4%, 1.7%) and MDR-TB incidence by 2.4% (95% UR: -5.2%, 9.1%) relative to existing practice but required 2,500 additional MDR-TB treatments and 60 four-module GeneXpert systems at maximum capacity. Further including 20% of unselected symptomatic individuals in the public sector required 700 systems and reduced incidence by 2.1% (95% UR: 0.5%, 3.9%); a similar approach involving qualified private providers (providers who have received at least some training in allopathic or non-allopathic medicine) reduced incidence by 6.0% (95% UR: 3.9%, 7.9%) with similar resource outlay, but only if high treatment success was assured. Engaging 20% of all private-sector providers (qualified and informal [providers with no formal medical training]) had the greatest impact (14.1% reduction, 95% UR: 10.6%, 16.9%), but required >2,200 systems and reliable treatment referral. Improving referrals from informal providers for smear-based diagnosis in the public sector (without Xpert rollout) had substantially greater impact (6.3% reduction) than Xpert scale-up within the public sector. These findings are subject to substantial uncertainty regarding private-sector treatment patterns, patient care-seeking behavior, symptoms, and infectiousness over time; these uncertainties should be addressed by future research.
conclusionsThe impact of new diagnostics for TB control in India depends on implementation within the complex, fragmented health-care system. Transformative strategies will require private/informal-sector engagement, adequate referral systems, improved treatment quality, and substantial resources. Please see later in the article for the Editors' Summary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.